679 results about "Tricyclic" patented technology

The present invention provides substituted tricyclic compound of formula (I), which are therapeutically useful as KRAS degraders. These compounds are useful in the treatment and / or prevention of diseases or disorders dependent upon KRAS. The present invention also provides pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt or a stereoisomer or a tautomer thereof thereof.

A tricyclic compound as a VHL ligand, a preparation method therefor, and a use of the compound or a pharmaceutical composition thereof for preventing and / or treating a series of diseases, disorders, and conditions.

The present application provides tricyclic triazolo compounds that modulate the activity of diacylglycerol kinase (DGK), which are useful in the treatment of various diseases, including cancer.

The invention relates to a tricyclic derivative inhibitor as well as a preparation method and application thereof. In particular, the invention relates to a tricyclic derivative compound, a preparation method thereof, a pharmaceutical composition containing the compound, and an application of the compound in treating cancers.

The invention belongs to the field of perovskite solar cells, and particularly relates to application of a bulk phase and interface synergistic passivator in a perovskite solar cell. The invention provides a bulk phase / interface synergistic passivation innovative strategy, molecules with a tricyclic sulfur-nitrogen heterocyclic ring structure are introduced as a synergistic passivator, and defect global repair of each functional layer of a device is realized. The molecular design of the structural derivative taking phenothiazine as the core has the following advantages: skeleton characteristics: a conjugated tricyclic system forms an electron transport network through pi-pi stacking, endows molecules with excellent electron delocalization ability, and effectively regulates and controls carrier kinetics; the thioether group is used for dynamically repairing an ion migration channel through oxidation-reduction activity and inhibiting formation of deep-energy-level defects; and the secondary amine group is used as a hydrogen bond donor for anchoring uncoordinated halide ions and synchronously passivating surface and grain boundary defects.

The invention relates to PRMT5 inhibitors of formula (I), a stereoisomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer thereof, a pharmaceutically acceptable salt of the atropisomer thereof, or a deuterated molecule thereof, and pharmaceutical compositions thereof, as well as the use thereof.

The present disclosure relates generally to compounds, of Formula (I). Also disclosed are pharmaceutical compositions comprising said compounds and methods of making said compounds. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.

Disclosed are compounds of Formula (I) or a salt or prodrug thereof, wherein: X1 and X2 are independently C or N, provided that zero or one of X1 and X2 is N; Ring A represented by the structure is: or; and Q, R1, R2, R3, R4, R6, and p are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.

The present disclosure relates generally to compounds, of Formula I: Also disclosed are pharmaceutical compositions comprising said compounds and methods of making said compounds. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.

The invention relates to a tricyclic compound as well as a preparation method and application thereof. The structural formula of the tri-fused ring compound is as shown in formula (I): # imgabs0 #, wherein R1, R2, R3, R4, R5, R6, R7, E, X and Y are as described in the specification. The compound can inhibit PDE3 and PDE4 at the same time, and compared with an existing PDE3 and PDE4 double-target inhibitor, the effect is better.

The present disclosure relates generally to compounds, of Formula (I). Also disclosed are pharmaceutical compositions comprising said compounds and methods of making said compounds. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.

The invention provides a tricyclic fused heterocyclic PDE3 / 4 dual inhibitor as well as a preparation method and application thereof, and particularly provides a compound with a structural formula I or a pharmaceutically acceptable form thereof, and each substituent group is defined in the specification. The compound or the pharmaceutically acceptable form of the compound can be used as a phosphodiesterase inhibitor and has relatively high activity. # imgabs0 #

The present application relates to a novel tricyclic derivative compound as a KRAS mutant protein inhibitor, and use thereof. The compound according to one embodiment of the present application inhibits the activity of a KRAS mutant protein and thus can be used in the prevention or treatment of diseases induced by KRAS mutation.

Disclosed are compounds of Formula I (shown below), methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.

Provided are a fused tricyclic compound, a preparation method therefor and a pharmaceutical use thereof. Specifically, provided are a compound as shown in general formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and a use thereof as a therapeutic agent, particularly a use as an RAS inhibitor and a use in the preparation of a drug for treating and / or preventing RAS-mediated or RAS-dependent diseases or disorders. The groups in general formula (I) are as defined in the description.

The invention provides a tricyclic fused heterocyclic PDE3 / 4 dual inhibitor as well as a preparation method and application thereof, and particularly provides a compound with a structural formula I or a pharmaceutically acceptable form thereof, and each substituent group is defined in the specification. The compound or the pharmaceutically acceptable form of the compound can be used as a phosphodiesterase inhibitor and has relatively high activity. # imgabs0 #

Disclosed are compounds of Formula I, shown below, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.

The invention relates to a tricyclic derivative inhibitor as well as a preparation method and application thereof. In particular, the invention relates to a tricyclic derivative compound, a preparation method thereof, a pharmaceutical composition containing the compound, and an application of the compound in treating cancers.

The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.

Processes and methods of preparing Compound (I) are disclosed. Crystalline forms of Compound (I), pharmaceutically acceptable salts, solvates, hydrates, and cocrystals thereof, pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.

The invention discloses a tricyclic fused heterocyclic PDE3 / 4 dual inhibitor, and a preparation and use therefor. Specifically provided is a compound having structural formula (I) or a pharmaceutically acceptable form thereof, wherein each substituent is as defined in the description, respectively. The compound or the pharmaceutically acceptable form thereof can be used as a phosphodiesterase inhibitor and has high activity.

The present disclosure relates generally to compounds, of Formula I.Also disclosed are pharmaceutical compositions comprising said compounds and methods of making said compounds. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.

Described herein are tricyclic PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer. Also disclosed herein is a method of treating brain cancer in a subject in need thereof, comprising administering a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. In some embodiments, the compound, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, is brain-penetrating.

Disclosed are compounds of the general formula (I), its tautomeric form, its stereoisomer, its pharmaceutically acceptable salt, its polymorph, or solvate thereof, Formula (I) wherein, ring A, R1 to R5, X, Y, m, and n are as defined herein, for use as SOS1 inhibitors in the treatment of proliferative, infectious and RASopathy diseases or disorders. Also disclosed are methods of synthesizing the compound of formula I, pharmaceutical compositions containing the compound of formula I, method of treatment of proliferative, infectious and RASopathy diseases or disorder, for example, a cancer, by administering the said compound and combinations of the compound of formula I with other active ingredients.

The present application relates to tricyclic compounds and medical use thereof. The structure is represented by formula (I). Specifically, the present application further relates to a preparation method for the compounds, a pharmaceutical composition, and use thereof in the treatment of cancers.

Provided herein are certain aminoheteroaryl compounds with tricyclic structure moiety, pharmaceutical compositions, and methods of use related to cyclin dependent kinases (CDKs). The compounds provided herein are typically CDK4 inhibitors, which can be used for treating a variety of diseases or disorders, such as cancer.

Provided herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof. The provided compounds are useful Protein arginine N-methyltransferase 5 (PRMT5) inhibitors. Also, disclosed are pharmaceutical compositions comprising such compounds and methods of making such compounds. Additional utilities and advantages are described herein.

The present disclosure is directed to compounds of Formula I:and pharmaceutically acceptable salts thereof, and compositions thereof, as well as methods of treatment of cancers such as those involving WRN protein.

Provided herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof. The provided compounds are useful Protein arginine N-methyltransferase 5 (PRMT5) inhibitors. Also, disclosed are pharmaceutical compositions comprising such compounds and methods of making such compounds. Additional utilities and advantages are described herein.